In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alexion Pharmaceuticals Inc.

http://www.alexion.com

Latest From Alexion Pharmaceuticals Inc.

IQVIA Notes Increasing Share Of Deals Between Smaller Biopharmas

In its 2023 report on global R&D trends for the biopharma sector, IQVIA found a shrinking percentage of deals involving $5bn+ revenue companies; R&D spending among big pharmas is the highest since 2014.

Business Strategies Deals

Finance Watch: Frontier Raises $80m For Differentiated KRAS G12C Program

Private Company Edition: With its lead program in the clinic, Frontier’s $80m series C round will fund trials for additional programs. Also, ORI raises $260m for second fund, Earlybird closed a €173m ($187.1m) fund, Areteia’s series A grew to $425m and Sudo’s series B increased to $147m.

Financing Innovation

Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance

Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.

Drug Approval Standards Clinical Trials

Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes

Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.

Clinical Trials Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
    • AstraZeneca PLC
    • AstraZeneca Rare Disease
    • Enobia Pharma Corp.
    • LogicBio Therapeutics, Inc.
    • Portola Pharmaceuticals, Inc. (PTLA)
    • Synageva BioPharma Corp.
    • Syntimmune, Inc.
    • Taligen Therapeutics, Inc.
    • Wilson Therapeutics AB
UsernamePublicRestriction

Register